Noelia Mancebo-Salas

Noelia Mancebo-Salas

Auto-generated profile, based on publicly available information

Noelia Mancebo-Salas

General Directorate of Social Services With the Ministry of Family, Youth and Social Policy of the, Community of Madrid, Madrid, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2024 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
PBPatricia Blázquez-González
Patricia Blázquez-González
Rubén Mirón-GonzálezRubén Mirón-González
Rubén Mirón-González
ALAlejandro Lendinez-Mesa
Alejandro Lendinez-Mesa
RLRaquel Luengo-Gonzalez
Raquel Luengo-Gonzalez
NMNoelia Mancebo-Salas
Noelia Mancebo-Salas
MGMontserrat García-Sastre
Montserrat García-Sastre
Background: In the different published studies, there is no consensus on the efficacy of virtual reality as an adjuvant treatment of mood states. Aim: The aim of this study is to evaluate the impact of no immersive virtual reality with the Nintendo Switch device in rehabilitation treatment on mood, anxiety and depression in stroke patients admitted to neurorehabilitation units. Methods: Fifty-eight patients admitted to neurorehabilitation units underwent a 1:3 multicentre randomised clinical trial. The intervention group consisted of 17 patients and the control group of 41 patients. The intervention group performed 6 virtual reality sessions together with the conventional treatment, and the control group performed only the conventional rehabilitation sessions. Primary and secondary clinical outcomes were measured before and six weeks after the intervention. Results: Comparing the intervention group and control group, the anxiety levels of the intervention group decreased compared to the results observed in the control group (p = 0.01), as did the dependence of the intervention group (0.015). On the other hand, the results obtained after the intervention by the control group for anxiety (0.479) and depression (0.292) were not statistically significant. Conclusion: Rehabilitation VR used as an adjuvant treatment to conventional treatment has a beneficial impact on the neurological status and state of anxiety of stroke patients admitted to neurorehabilitation units. Trial registration: Registered in the https://clinicaltrials.gov/ repository (NTC NCT05143385). Protocol registration date 7 October 2021, retrospectively registered.

27 December 2023 in Worldviews on Evidence-Based Nursing
Verified
Journal Article
Open access
PBPatricia Blázquez‐González
Patricia Blázquez‐González
Rubén Mirón-GonzálezRubén Mirón-González
Rubén Mirón-González
ALAlejandro Lendinez-Mesa
Alejandro Lendinez-Mesa
RLRaquel Luengo-Gonzalez
Raquel Luengo-Gonzalez
NMNoelia Mancebo‐Salas
Noelia Mancebo‐Salas
JMJosé Alberto Martínez‐Hortelano
José Alberto Martínez‐Hortelano
Background: Post‐stroke depression is the most common neuropsychiatric consequence and reduces rehabilitation effectiveness. However, the efficacy of virtual reality (VR) on mental health treatment for patients after a stroke is uncertain.Aims: The aim of this study was to evaluate the efficacy of VR as a co‐adjuvant form of treatment to reduce depression in stroke patients admitted to neurorehabilitation units.Methods: We systematically searched medical databases including PubMed, CINAHL, PsycINFO, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception to November 16, 2023. Clinical trials comparing the use of VR as an adjuvant form of treatment in stroke patients' rehabilitation with the usual treatment were included. Pooled standardized mean differences were calculated using a random‐effects model. Subgroup analyses were performed according to type of stroke, VR characteristics, and the scale used to measure depression. Meta‐regression analysis was performed for intervention duration and to determine the mean age of the participants.Results: Eight studies and 388 stroke patients were included. The VR interventions were associated with a lower risk of depression in patients (ES = −0.69; 95% CI [−1.05, −0.33]; I2 = 57.6%; p ≤ .02). The estimates were not affected by the type of stroke, the type of VR used, the blinding process, the type of scale used to detect depression, the duration of the intervention (weeks and minutes), and the total number of sessions. Meta‐regression shows that younger samples (p = .00; 95% CI [0.01, 0.08) and longer interventions (p = < .05; 95% CI [−0.00, −0.00) lead to a greater reduction in depression.Linking Evidence to Action: This review provides an important basis for treating depression in patients after a stroke. Professionals working in stroke neurorehabilitation units should consider VR as a form of co‐adjuvant treatment for depression in patients.Systematic Review Registration: CRD42022303968.

6 September 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
José Luis Cobo-SanchezJosé Luis Cobo-Sanchez
José Luis Cobo-Sanchez
IBIan Blanco-Mavillard
Ian Blanco-Mavillard
RPRaquel Pelayo-Alonso
Raquel Pelayo-Alonso
NMNoelia Mancebo-Salas
Noelia Mancebo-Salas
IFIsmael Fernandez-Fernandez
Ismael Fernandez-Fernandez
JPJoan Ernest De Pedro-Gomez
Joan Ernest De Pedro-Gomez
Introduction: Haemodialysis patients with central venous catheter (HD-CVC) are at increased risk of exit site infections (ESIs) and catheter-related bloodstream infections, causing an increase of hospitalisation, morbidity and mortality rates. The main aim of the EXITA Study is to develop and validate an instrument for the early detection of HD-CVC ESIs.Methods and analysis: EXITA is a multicentre prospective cohort study to validate the proposed instrument with a sample of 457 HD-CVCs: 92 in the ESI group and 365 in the non-ESI group. Sample size was calculated using Epidat V.4.2 software, with 95% and 90% expected sensitivity and specificity, respectively, an ESI incidence around 20% and 5%–10% precision range. During each haemodialysis session, the absence or presence of each item will be assessed by nurses. If any item is present, a microbiological study of pericatheter skin smears and/or exit site exudate will be carried out. HD-CVC ESI will be diagnosed when the pericatheter skin smears and/or exit site exudate culture are positive (≥15 CFU/mL by semiquantitative Maki’s technique or ≥1000 CFU/mL by Cleri’s technique). To validate the scale, a logistic regression analysis will be performed: the β coefficients of each of the signs/symptoms of the scale to be validated will be estimated. We will use logit function and calculate ESI probability=elogit ESI/1+elogit ESI.Ethics and dissemination: The study has been approved by the Research Ethics Committee with Medical Products of Cantabria (approval code 2019.146). We will obtain informed consent from all participants before data collection. We will publish the study results in a peer-reviewed scientific journal.

13 December 2023 in Journal of Clinical Nursing
Verified
Journal Article
Open access
José Luis Cobo-SanchezJosé Luis Cobo-Sanchez
José Luis Cobo-Sanchez
IBIan Blanco-Mavillard
Ian Blanco-Mavillard
NMNoelia Mancebo‐Salas
Noelia Mancebo‐Salas
RPRaquel Pelayo‐Alonso
Raquel Pelayo‐Alonso
ZGZulema Gancedo-González
Zulema Gancedo-González
JPJoan Ernest De Pedro‐Gómez
Joan Ernest De Pedro‐Gómez
AimTo evaluate the relevance of signs and symptoms for the clinical identification of ESI and TI in HD-CVC, by means of international expert consensus, and to reach a consensus on a definition and clinical management (CM) for these infections.BackgroundA recent systematic review showed a high heterogeneity in the signs/symptoms used for determining exit site infection (ESI) and tunnel infection (TI) of haemodialysis central venous catheter (HD-CVC).DesignA modified Delphi ranking process was carried out between November 2020 and March 2021, consisting of four rounds using an online questionnaire with a panel of 26 experts from 12 countries.MethodsExperts responded on the level of relevance for the identification of ESI and TI, based on a list of 22 signs/symptoms obtained from a previous systematic review, using a 4-point Likert-type scale. After reaching consensus on the signs/symptoms, they followed the same method to reach consensus on the CM. The STROBE Checklist was used to report this study.ResultsA high degree of consensus was reached to identify the presence of ESI based on nine signs/symptoms: presence of pain at the exit site (ES) during interdialysis period, with fever >= 38 degrees C do not suspect other cause, local signs at the ES (inflammation, induration, swelling, hyperemia/erythema >= 2 cm from ES) and obvious abscess or purulent exudate at ES; and of TI. Likewise, 5 cm were agreed upon.ConclusionThis Delphi study provides international expert consensus definitions of ESI and TI in HD-CVC, laying the groundwork for the validation of an HD-CVC ES clinical assessment scale for early identification of ESI.Relevance to Clinical PracticeIn addition, this study provides a series of attitudes to consensual clinics regarding signs/symptoms of local infections in HD-CVC, which may be useful as expert opinion in clinical practice guidelines, when there is insufficient scientific evidence.

30 June 2021 in Enfermería Nefrológica
Verified
Journal Article
Open access
PDF file
VSVictoria Sancha-Escudero
Victoria Sancha-Escudero
José Luis Cobo-SanchezJosé Luis Cobo-Sanchez
José Luis Cobo-Sanchez
NMNoelia Mancebo-Salas
Noelia Mancebo-Salas
RPRaquel Pelayo-Alonso
Raquel Pelayo-Alonso
ZGZulema Gancedo-González
Zulema Gancedo-González
The most recent literature indicates that chronic kidney disease is the comorbidity with the highest risk of developing severe disease due to SARS-CoV-2, coronavirus 2019 (COVID-19). Many scientific societies have positioned themselves in favor of the vaccination of patients with chronic kidney disease as a priority, due to this high vulnerability. In Spain, the fifth update of the Vaccination Strategy against COVID-19 of the Interterritorial Health Council, included patients with CKD in group 7 (people with very high-risk conditions). Throughout the article, the types of vaccines are described accordingly to the mechanism of action, the vaccines currently approved by the European Medicines Agency (EMA) and everything related to the vaccination process (preparation, administration and monitoring), in addition to the aspects to take into account in patients with chronic kidney disease.